Navigation Links
Researchers design model for automated, wearable artificial kidney
Date:7/10/2008

Two researchers from UCLA and the Veterans Affairs Greater Los Angeles Healthcare System have developed a design for an automated, wearable artificial kidney, or AWAK, that avoids the complications patients often suffer with traditional dialysis.

The design for the peritoneal-based artificial kidney which is "bloodless" and reduces or even eliminates protein loss and other dialysis-related problems is summarized in an article published in the current issue of the journal Clinical and Experimental Nephrology, available online at http://dx.doi.org/10.1007/s10157-008-0050-9.

UCLAVA has also signed an exclusive licensing agreement with the Singapore-based company AWAK Technologies Pte. Ltd. to develop a commercial wearable kidney based on the design by Martin Roberts, an assistant professor of clinical medicine at the David Geffen School of Medicine at UCLA and a dialysis consultant with the VA Healthcare System, and David B.N. Lee, a professor of medicine at the Geffen School and a consultant nephrologist at the VA.

Around 1980, an artificial kidney machine was built that incorporated many of the principles on which the new technology relies, according to Roberts. But that machine, while portable, was not wearable. The new technology would allow patients to go about their regular business while undergoing dialysis.

"What's really new about it is the patient's freedom," Roberts said. "To me, as the inventor, the most important thing for the patients is their freedom. The next important thing is that because it's working all the time instead of intermittently, you can do a much better job of treating the patient. So we expect the patient to feel better and live longer."

Kidneys remove metabolic wastes from the body and regulate fluid volume and distribution on a continuous, around-the-clock basis. With traditional hemodialysis, patients are hooked up to a machine for four hours, three times a week. Their blood is filtered through the machine to remove toxins and is then pumped back into the body. What hemodialysis can't do, however, is provide cleansing and fluid balance on a continuous basis; therefore, toxin levels and fluid volume tend to fluctuate, causing "shocks" to the patient's system. The same is true of standard peritoneal-based dialysis.

In addition, hemodialysis uses anticoagulants to prevent the blood circulating outside the body from clotting. But this, too, can cause complications. Work on other wearable kidneys has been based on this hemodialysis or hemofiltration model.

The AWAK, on the other hand, would function continuously, as natural kidneys do, eliminating patient "shocks." And because it does not involve blood circulation outside the body, it is "bloodless." It also regenerates and reuses fluid and protein components in the spent dialysate the fluid that has abstracted toxins from the patient's blood and which is discarded in current practice making it waterless and minimizing or eliminating protein loss.

"Dialysis-on-the-go, made possible by AWAK's 'wearability' and automation, frees end-stage renal failure patients from the servitude that is demanded by the current dialytic regimentations," Roberts and Lee write in the journal article.


'/>"/>

Contact: Enrique Rivero
erivero@mednet.ucla.edu
310-794-2273
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Summer storms are inevitable ... havoc across communities and often result in massive tree damage requiring emergency tree service. ... take now including tree trimming, tree cabling and hazardous tree removal. , ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... out how to change manufacturers future. , The agency is hammering out a ... Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The new ...
(Date:7/24/2017)... Long Island (PRWEB) , ... July 24, 2017 ... ... of a new office at 2307 Bellmore Avenue, Bellmore, New York, (516) 784-5858. ... dermatologist Jordan Fabrikant, M.D. and physician assistants Lori Friedman and Fruma Leah Wiederman. ...
(Date:7/24/2017)... ... July 24, 2017 , ... “Nana Nana Boo Boo”: ... of being kind to others. “Nana Nana Boo Boo” is the creation of published ... , Published by Christian Faith Publishing, Michael Rush’s new book presents the importance ...
(Date:7/24/2017)... ... , ... “Journey to the Light: The Quest for Happiness and Love. . ... to finding herself. “Journey to the Light: The Quest for Happiness and Love. ... writer of newsletters, manuals, and articles, who has recently decided to expand her literary ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology: